Literature DB >> 9165689

Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions.

U A Meyer1.   

Abstract

Omeprazole, lansoprazole and pantoprazole are metabolized by several human cytochromes P450, most prominently by CYP2C19 and CYP3A4. Only pantoprazole is also metabolized by a sulfotransferase. Differences in the quantitative contribution of these enzymes and in the relative affinities of the substrates explain some of the observed interactions with carbamazepin, diazepam, phenytoin and theophylline and of the impact of the CYP2C19 (mephenytoin) genetic polymorphism. Of these drugs, pantoprazole has the lowest potential for interactions, both in vitro and in human volunteer studies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9165689      PMCID: PMC2589004     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  32 in total

1.  Influence of lansoprazole treatment on diazepam plasma concentrations.

Authors:  R A Lefebvre; B Flouvat; S Karolac-Tamisier; E Moerman; E Van Ganse
Journal:  Clin Pharmacol Ther       Date:  1992-11       Impact factor: 6.875

2.  Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population.

Authors:  D R Sohn; K Kobayashi; K Chiba; K H Lee; S G Shin; T Ishizaki
Journal:  J Pharmacol Exp Ther       Date:  1992-09       Impact factor: 4.030

3.  Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole.

Authors:  T Andersson; C Cederberg; G Edvardsson; A Heggelund; P Lundborg
Journal:  Clin Pharmacol Ther       Date:  1990-01       Impact factor: 6.875

4.  Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators.

Authors:  T Andersson; C G Regårdh; M L Dahl-Puustinen; L Bertilsson
Journal:  Ther Drug Monit       Date:  1990-07       Impact factor: 3.681

5.  Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450.

Authors:  D Diaz; I Fabre; M Daujat; B Saint Aubert; P Bories; H Michel; P Maurel
Journal:  Gastroenterology       Date:  1990-09       Impact factor: 22.682

6.  Omeprazole, an inducer of human CYP1A1 and 1A2, is not a ligand for the Ah receptor.

Authors:  M Daujat; B Peryt; P Lesca; G Fourtanier; J Domergue; P Maurel
Journal:  Biochem Biophys Res Commun       Date:  1992-10-30       Impact factor: 3.575

7.  Induction of cytochrome P450IA genes (CYP1A) by omeprazole in the human alimentary tract.

Authors:  W M McDonnell; J M Scheiman; P G Traber
Journal:  Gastroenterology       Date:  1992-11       Impact factor: 22.682

8.  Nuclear uptake of the Ah (dioxin) receptor in response to omeprazole: transcriptional activation of the human CYP1A1 gene.

Authors:  L C Quattrochi; R H Tukey
Journal:  Mol Pharmacol       Date:  1993-04       Impact factor: 4.436

9.  Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism.

Authors:  T Andersson; J O Miners; M E Veronese; W Tassaneeyakul; W Tassaneeyakul; U A Meyer; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

10.  Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro.

Authors:  R Gugler; J C Jensen
Journal:  Gastroenterology       Date:  1985-12       Impact factor: 22.682

View more
  19 in total

1.  CYP2C19-guided design of a proton pump inhibitor dose regimen to avoid the need for pharmacogenetic individualization in H. pylori eradication.

Authors:  Michael B Ward; David J R Foster
Journal:  Eur J Clin Pharmacol       Date:  2010-11-16       Impact factor: 2.953

2.  Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources.

Authors:  Gianluca Trifirò; Salvatore Corrao; Marianna Alacqua; Salvatore Moretti; Michele Tari; Achille P Caputi; Vincenzo Arcoraci
Journal:  Br J Clin Pharmacol       Date:  2006-07-06       Impact factor: 4.335

3.  Pharmacokinetics of lacosamide and omeprazole coadministration in healthy volunteers: results from a phase I, randomized, crossover trial.

Authors:  Willi Cawello; Christa Mueller-Voessing; Andreas Fichtner
Journal:  Clin Drug Investig       Date:  2014-05       Impact factor: 2.859

Review 4.  Optimizing the Use of Medications and Other Therapies in Infant Gastroesophageal Reflux.

Authors:  Steven L Ciciora; Frederick W Woodley
Journal:  Paediatr Drugs       Date:  2018-12       Impact factor: 3.022

5.  Exploration of the binding of proton pump inhibitors to human P450 2C9 based on docking and molecular dynamics simulation.

Authors:  Rongwei Shi; Jinyu Li; Xiaoning Cao; Xiaolei Zhu; Xiaohua Lu
Journal:  J Mol Model       Date:  2010-12-01       Impact factor: 1.810

6.  Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.

Authors:  Barbara Gawrońska-Szklarz; Joanna Wrześniewska; Teresa Starzyńska; Andrzej Pawlik; Krzysztof Safranow; Katarzyna Ferenc; Marek Droździk
Journal:  Eur J Clin Pharmacol       Date:  2005-06-23       Impact factor: 2.953

Review 7.  Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions.

Authors:  D A Flockhart; Z Desta; S K Mahal
Journal:  Clin Pharmacokinet       Date:  2000-10       Impact factor: 6.447

Review 8.  Pharmacokinetics of proton pump inhibitors in children.

Authors:  Catherine Litalien; Yves Théorêt; Christophe Faure
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

9.  Liver hepatotoxicity associated with pantoprazole: a rare case report.

Authors:  Mehmet Aslan; Yilmaz Celik; Sevdegul Karadas; Sehmus Olmez; Adem Cifci
Journal:  Wien Klin Wochenschr       Date:  2014-03-21       Impact factor: 1.704

10.  Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drug-drug interaction.

Authors:  Srecko Marusic; Ante Lisicic; Ivica Horvatic; Vesna Bacic-Vrca; Nada Bozina
Journal:  Int J Clin Pharm       Date:  2012-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.